Open AccessMinocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens
Author(s) -
Dee Shortridge,
S J Ryan Arends,
Jennifer M Streit,
Mariana Castanheira
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01264-21
Subject(s) - stenotrophomonas maltophilia , burkholderia , microbiology and biotechnology , achromobacter , stenotrophomonas , aeromonas , chryseobacterium , alcaligenes faecalis , alcaligenes , biology , pseudomonas aeruginosa , pseudomonas , bacteria , genetics , 16s ribosomal rna
The minocycline susceptibility of 3,856 isolates including Burkholderia , Achromobacter , Alcaligenes , Aeromonas , and Stenotrophomonas maltophilia from the SENTRY surveillance (2014 to 2019) were analyzed. The susceptibilities of these species (%S) were Achromobacter spp. ( n = 411; 92.6%), Burkholderia cepacia species complex ( n = 199; 85.9%), Aeromonas spp. ( n = 127; 99.2%), Chryseobacterium spp. ( n = 59; 94.9%), Alcaligenes faecalis ( n = 42; 88.1%), and S. maltophilia ( n = 2,287; 99.5%). These data suggest that minocycline is a useful treatment option for infections caused by unusual Gram-negative pathogens.